The FDA has granted Breakthrough Therapy designation to daraxonrasib, the RAS-blocking pill sold as Rasonque, for use with standard chemotherapy in people with metastatic pancreatic cancer who have not yet been treated. Developer Revolution Medicines announced the designation on Sept. 14, less than three weeks after the drug's first FDA approval.
The designation covers daraxonrasib combined with gemcitabine and nab-paclitaxel, a chemotherapy regimen widely used for this cancer. Using that combination first would move the drug to the start of care instead of reserving it for patients who have already been treated.
